National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.

Rapid Review

Commenced Completed Outcome
26/04/2011 20/06/2011 Full Pharmacoeconomic Evaluation Recommended.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.